01:27 , Oct 20, 2015 |  BC Extra  |  Financial News

NantWorks invests $50M in Precision Biologics

NantWorks LLC (Los Angeles, Calif.) invested $50 million in Precision Biologics Inc. (Dallas, Texas), giving it a majority stake in the company. Precision Biologics is developing a pipeline of mAbs and companion diagnostics to treat...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

Ensituximab: Completed Phase II enrollment

Precision completed enrollment of 47 patients in an open-label, U.S. Phase II trial evaluating 3 mg/kg IV NPC-1C once every 2 weeks. Precision Biologics Inc., Dallas, Texas   Product: Ensituximab ( NEO-101, NPC-1C)   Business: Cancer...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Clinical News

NEO-102: Interim Phase I/IIa data

Interim data from 9 evaluable patients with refractory metastatic pancreatic and colorectal cancer in an open-label, U.S. Phase I/IIa trial showed that IV NEO-102 led to 5 cases of stable disease. Of the 16 patients...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

Ensituximab: Phase I/IIa data

Preliminary data from 17 evaluable patients with advanced pancreatic and colorectal cancer who progressed on standard therapy in the Phase IIa portion of an open-label, U.S. Phase I/IIa trial showed that 1.5 mg/kg IV ensituximab...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Clinical News

Ensituximab: Phase I data

An open-label, dose-escalation Phase I trial in 15 patients with advanced pancreatic and colorectal cancer who progressed on standard therapy showed that 1.5 mg/kg IV ensituximab every 2 weeks for 8 weeks was well tolerated...
07:00 , Oct 4, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza Mucin 5AC oligomeric mucus/gel-forming (MUC5AC) Mouse studies suggest increasing MUC5AC levels in the lungs could...